Inventor · disambiguated record
Alexis Henri Abel Mollard
Also filed as: MOLLARD ALEXIS · MOLLARD ALEXIS HENRI ABEL
11 granted patents·11 pending applications·64 citations·filing 2012–2023
89Inventor score
Files withHALIA THERAPEUTICS INC15MANNKIND CORP2TOLERO PHARMACEUTICALS INC2BEARSS DAVID J1SUMITOMO DAINIPPON PHARMA ONCOLOGY INC1
Top patents by PatentIndex Score
22 records- 0195US11161852B1Inhibitors of NEK7 kinaseHALIA THERAPEUTICS INC·Filed 2021·Granted Nov 2, 2021·8 cites·27 claims
- 0294US11578061B2Inhibitors of LRRK2 kinaseHALIA THERAPEUTICS INC·Filed 2022·Granted Feb 14, 2023·3 cites·27 claims
- 0393US11866423B2Inhibitors of LRRK2 kinaseHALIA THERAPEUTICS INC·Filed 2022·Granted Jan 9, 2024·2 cites·26 claims
- 0493US8901120B2Substituted N-phenylpyrimidin-2-amine analogs as inhibitors of the Axl kinaseBEARSS DAVID J·Filed 2012·Granted Dec 2, 2014·17 cites·31 claims
- 0592US10202356B2JAK2 and ALK2 inhibitors and methods for their useTOLERO PHARMACEUTICALS INC·Filed 2014·Granted Feb 12, 2019·12 cites·10 claims
- 0691US11713321B2Inhibitors of NEK7 kinaseHALIA THERAPEUTICS INC·Filed 2021·Granted Aug 1, 2023·2 cites·22 claims
- 0790US9493454B2Multiple kinase pathway inhibitorsMANNKIND CORP·Filed 2013·Granted Nov 15, 2016·13 cites·24 claims
- 0888US9714247B2Multiple kinase pathway inhibitorsMANNKIND CORP·Filed 2016·Granted Jul 25, 2017·6 cites·10 claims
- 0983US12428404B2Inhibitors of LRRK2 kinaseHALIA THERAPEUTICS INC·Filed 2023·Granted Sep 30, 2025·0 cites·22 claims
- 1083US10752594B2JAK1 and ALK2 inhibitors and methods for their useTOLERO PHARMACEUTICALS INC·Filed 2018·Granted Aug 25, 2020·1 cites·11 claims
- 1179US2024083855A1Jak2 and alk2 inhibitors and methods for their useSUMITOMO PHARMA AMERICA INC·Filed 2023·Application pending·0 cites
- 1278US12091413B2Inhibitors of NEK7 kinaseHALIA THERAPEUTICS INC·Filed 2023·Granted Sep 17, 2024·0 cites·20 claims
- 1369US2021070715A1Jak2 and alk2 inhibitors and methods for their useSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2020·Application pending·0 cites
- 1463US2024158394A1Nek7 inhibitorsHALIA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1560US2025019378A1Pyrrole[2,3-b]pyridine derivatives as tyro3 inhibitorsHALIA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1659US2024425499A1Tyro3 inhibitorsHALIA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1757US2024382488A1Nek7 inhibitorsHALIA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1857US2025177382A1Nek7 inhibitorsHALIA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1957US2024317758A1Nek7 inhibitorsHALIA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2056US2024400551A1Nek7 inhibitorsHALIA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2154US2023210853A1Targeted nek7 inhibition for modulation of the nlrp3 inflammasomeHALIA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2253US2023203045A1Inhibitors of nek7 kinaseHALIA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →